RESUMEN
Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare, chronic, inflammatory disorder with cutaneous and osteoarticular manifestations.1 The aetiology of SAPHO syndrome is unknown and therefore treatment is tailored towards the individual. Non-steroidal anti-inflammatory drugs, bisphosphonates, corticosteriods, antibiotics, disease modifying anti-rheumatic drugs and biologics have all been used with variable success.
Asunto(s)
Síndrome de Hiperostosis Adquirido , Acné Vulgar/etiología , Acné Vulgar/patología , Síndrome de Hiperostosis Adquirido/complicaciones , Síndrome de Hiperostosis Adquirido/diagnóstico por imagen , Síndrome de Hiperostosis Adquirido/patología , Femenino , Humanos , Persona de Mediana Edad , Psoriasis/etiología , Psoriasis/patología , Cintigrafía , Articulación Sacroiliaca/diagnóstico por imagen , Articulación Sacroiliaca/patología , Piel/patología , Articulación Esternoclavicular/diagnóstico por imagen , Articulación Esternoclavicular/patología , Imagen de Cuerpo EnteroAsunto(s)
Exantema/patología , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Mycobacterium chelonae/aislamiento & purificación , Biopsia con Aguja , Claritromicina/uso terapéutico , Quimioterapia Combinada , Exantema/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Extremidad Inferior , Persona de Mediana Edad , Ácido Micofenólico/uso terapéutico , Resultado del TratamientoRESUMEN
OBJECTIVES: Gemcitabine in combination with capecitabine (GEMCAP) is a treatment option for patients with advanced pancreatic cancer (APC), but data are lacking concerning outcomes in unselected patients not enrolled to a randomized trial. METHODS: Baseline demographic, clinical, toxicity, tumor response, and survival data were collected for previously untreated patients with APC receiving off-protocol GEMCAP at a single institution between 2005 and 2009. RESULTS: Data from 113 patients were included in the study. The mean age was 65 years; 51% of patients had metastatic disease; and 80% were of World Health Organization performance status 0 or 1. Patients received a mean of 20 weeks of chemotherapy. The objective response rate was 9.7%; the median overall survival was 8.7 months (95% confidence interval, 6.7-10.7), and 34% of patients were alive 1 year after starting treatment. Performance status (0 or 1 vs 2) was a significant prognostic factor (P < 0.0001). Grade 3 or 4 adverse events, excluding nonfebrile neutropenia, were experienced by 37 patients (33%), the commonest being lethargy (8%), hand-foot syndrome (8%), diarrhea (7%), thrombocytopenia (4%), and febrile neutropenia (6%). CONCLUSIONS: Gemcitabine in combination with capecitabine is effective and tolerable in unselected patients with APC, and outcomes are comparable with those of patients receiving GEMCAP in clinical trials.
